News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
580,597 Results
Type
Article (19058)
Company Profile (166)
Press Release (561371)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (198387)
Career Advice (702)
Deals (30745)
Drug Delivery (86)
Drug Development (65643)
Employer Resources (54)
FDA (12400)
Job Trends (11096)
News (287858)
Policy (24143)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (818)
Accelerated approval (41)
ADA (26)
Adcomms (10)
Allergies (142)
Alliances (41808)
ALS (142)
Alzheimer's disease (1268)
Antibody-drug conjugate (ADC) (348)
Approvals (13021)
Artificial intelligence (507)
ASCO (219)
Autoimmune disease (251)
Automation (40)
Bankruptcy (319)
Best Places to Work (8366)
BIO (47)
BIOSECURE Act (10)
Biosimilars (189)
BioSpace Insights (76)
Biotechnology (102)
Bladder cancer (155)
Brain cancer (55)
Breast cancer (599)
Cancer (4456)
Cardiovascular disease (350)
Career advice (607)
Career pathing (15)
CAR-T (218)
CDC (8)
Celiac Disease (1)
Cell therapy (608)
Cervical cancer (41)
Clinical research (58819)
Collaboration (1710)
Commercialization (3)
Company closure (1)
Compensation (1463)
Complete response letters (61)
COVID-19 (1284)
CRISPR (82)
C-suite (1036)
Cystic fibrosis (124)
Data (6572)
Decentralized trials (1)
Denatured (23)
Depression (125)
Dermatology (67)
Diabetes (439)
Diagnostics (4817)
Digital health (44)
Diversity (3)
Diversity, equity & inclusion (16)
Drug discovery (266)
Drug pricing (126)
Drug shortages (15)
Duchenne muscular dystrophy (230)
Earnings (81128)
Editorial (25)
Employer branding (5)
Employer resources (50)
Events (99189)
Executive appointments (960)
FDA (15528)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (20)
Frontotemporal dementia (27)
Funding (1210)
Gene editing (164)
Generative AI (35)
Gene therapy (459)
GLP-1 (674)
Government (2007)
Grass and pollen (5)
Guidances (331)
Healthcare (11030)
Hematology (128)
HIV (55)
Huntington's disease (28)
IgA nephropathy (99)
Immunology and inflammation (168)
Immuno-oncology (76)
Indications (194)
Infectious disease (1516)
Inflammatory bowel disease (173)
Inflation Reduction Act (9)
Influenza (97)
Intellectual property (292)
Interviews (93)
IPO (13975)
IRA (33)
Job creations (3104)
Job search strategy (550)
JPM (30)
Kidney cancer (20)
Labor market (39)
Layoffs (252)
Leadership (11)
Legal (6580)
Licensing (6)
Liver cancer (55)
Longevity (21)
Lung cancer (628)
Lymphoma (342)
Machine learning (35)
Management (18)
Manufacturing (899)
Marketing (11)
MASH (163)
Medical affairs (1)
Medical device (9255)
Medtech (9401)
Mergers & acquisitions (17933)
Metabolic disorders (1060)
mRNA (109)
Multiple sclerosis (139)
NASH (15)
Neurodegenerative disease (297)
Neuropsychiatric disorders (70)
Neuroscience (2421)
Neurotech (1)
NextGen: Class of 2026 (3893)
Non-profit (1255)
Now hiring (23)
Obesity (425)
Opinion (158)
Ovarian cancer (175)
Pain (242)
Pancreatic cancer (224)
Parkinson's disease (276)
Partnered (20)
Patents (573)
Patient recruitment (588)
Peanut (39)
People (50637)
Pharmaceutical (45)
Pharmacy benefit managers (23)
Phase 1 (18140)
Phase 2 (25869)
Phase 3 (19181)
Pipeline (8405)
Policy (165)
Postmarket research (2126)
Preclinical (7529)
Press Release (49)
Prostate cancer (235)
Psychedelics (30)
Radiopharmaceuticals (269)
Rare diseases (847)
Real estate (4459)
Recruiting (20)
Regulatory (19698)
Reports (23)
Research institute (955)
Resumes & cover letters (94)
Rett syndrome (42)
RNA editing (12)
RSV (53)
Schizophrenia (145)
Series A (220)
Series B (154)
Service/supplier (5)
Sickle cell disease (97)
Special edition (11)
Spinal muscular atrophy (113)
Sponsored (15)
Startups (2781)
State (2)
Stomach cancer (8)
Supply chain (95)
Tariffs (71)
The Weekly (53)
Vaccines (509)
Venture capital (55)
Weight loss (227)
Women's health (101)
Worklife (4)
Date
Today (41)
Last 7 days (609)
Last 30 days (1732)
Last 365 days (23106)
2026 (14234)
2025 (23301)
2024 (27244)
2023 (31378)
2022 (40746)
2021 (43341)
2020 (39851)
2019 (29695)
2018 (22622)
2017 (24679)
2016 (23524)
2015 (29423)
2014 (25668)
2013 (22072)
2012 (24093)
2011 (24438)
2010 (23670)
Location
Africa (466)
Alabama (80)
Alaska (2)
Arizona (329)
Arkansas (13)
Asia (30134)
Australia (4145)
California (12466)
Canada (3403)
China (1021)
Colorado (502)
Connecticut (456)
Delaware (270)
Europe (54603)
Florida (1898)
Georgia (399)
Hawaii (3)
Idaho (49)
Illinois (848)
India (92)
Indiana (553)
Iowa (15)
Japan (554)
Kansas (117)
Kentucky (36)
Louisiana (30)
Maine (27)
Maryland (1344)
Massachusetts (8596)
Michigan (321)
Minnesota (597)
Mississippi (5)
Missouri (103)
Montana (27)
Nebraska (16)
Nevada (115)
New Hampshire (68)
New Jersey (3145)
New Mexico (18)
New York (3070)
North Carolina (1495)
North Dakota (4)
Northern California (6230)
Ohio (298)
Oklahoma (16)
Oregon (31)
Pennsylvania (2382)
Puerto Rico (26)
Rhode Island (36)
South America (732)
South Carolina (79)
South Dakota (1)
Southern California (5137)
Tennessee (143)
Texas (1992)
United States (42277)
Utah (382)
Vermont (1)
Virginia (262)
Washington D.C. (51)
Washington State (969)
West Virginia (2)
Wisconsin (103)
Wyoming (1)
580,597 Results for "cyclacel pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT
May 7, 2025
·
3 min read
Business
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2024 financial results on Tuesday, May 14, 2024.
May 8, 2024
·
3 min read
Press Releases
Cyclacel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
·
8 min read
Press Releases
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock
June 23, 2025
·
5 min read
Pharm Country
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
Cyclacel Pharmaceuticals, Inc. announced the receipt of a notice from the European Patent Office of the intention to grant a patent which includes claims to novel pharmaceutical compositions of plogosertib, a PLK1 inhibitor.
June 26, 2024
·
5 min read
Business
Cyclacel Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced first quarter financial results and provided a business update.
May 14, 2024
·
8 min read
Press Releases
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
August 5, 2025
·
6 min read
Business
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024.
March 13, 2024
·
3 min read
Drug Development
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”) today announced a presentation by independent investigators of preclinical data demonstrating therapeutic potential of fadraciclib, the Company’s cyclin-dependent kinase (CDK) 2/9 inhibitor, as a novel treatment for metastatic colorectal cancer (CRC).
June 4, 2024
·
7 min read
Press Releases
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
May 15, 2025
·
7 min read
1 of 58,060
Next
